the identification of populations with a loss-of-function mutation in the PCSK9 gene having extremely low rates of heart disease (and otherwise being perfectly fine with little-to-no functional PCSK9 present) looks to be a game changer. There is already fast growth of so-called PCSK9 inhibitors such as Repatha which I'm now on. These treatments seem to be superior to statins in most ways except price + it's an injection, for the moment.
Comments
the identification of populations with a loss-of-function mutation in the PCSK9 gene having extremely low rates of heart disease (and otherwise being perfectly fine with little-to-no functional PCSK9 present) looks to be a game changer. There is already fast growth of so-called PCSK9 inhibitors such as Repatha which I'm now on. These treatments seem to be superior to statins in most ways except price + it's an injection, for the moment.